EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Diving into the Regulatory Landscape of Digital Therapeutics

Madhumitha Masilamani, Melvin George

Therapeutic Innovation & Regulatory Science · 2026-05 · 60 (3) · 725-735

DOI: 10.1007/s43441-026-00944-w ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Therapeutic Innovation & Regulatory Science, online erschienen am 05.03.2026. Verfasst von Madhumitha Masilamani und 1 weiteren Autor:innen. Beteiligte Einrichtung: SRM Centre for Clinical Pharmacology, Faculty of Medicine and Health Sciences, SRM Institute of Science and Technology, Kattankulathur, Chengalpattu,…. Hauptthemen laut MEDLINE: Digital Health, Therapeutics. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Digital therapeutics (DTx) are emerging as a transformative approach in healthcare, offering software-driven, evidence-based interventions for the prevention, management, and treatment of medical conditions such as chronic diseases, mental health disorders, and substance use disorders. Unlike general wellness applications or traditional digital health tools, DTx products are subject to rigorous clinical validation and regulatory scrutiny, ensuring their safety, efficacy, and integration into clinical practice. This manuscript explores the defining characteristics of digital therapeutics, differentiating them from other digital health technologies, and examines their role in patient-centric care. It further investigates global regulatory frameworks, including those in the United States, Europe, and Korea, highlighting the need for harmonized guidelines and structured approval pathways. The paper also discusses the importance of robust clinical trial design, validation methods, and post-market surveillance to support the adoption and reimbursement of DTx. Real-world examples such as EndeavorRx®, reSET, DaylightRx and Somryst illustrate the growing potential of DTx to reshape medical treatment. As digital therapeutics continue to evolve, this review emphasizes the critical need for regulatory agility, evidence-based implementation, and collaborative efforts to fully realize their benefits within modern healthcare systems.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Digital HealthTherapeuticsHumansUnited States

Stichwörter der Autor:innen

Digital therapeutics (DTx)Modern healthcarePatient-centricRegulatoryRegulatory framework

Autor:innen und Institutionen

  • SRM Centre for Clinical Pharmacology, Faculty of Medicine and Health Sciences, SRM Institute of Science and Technology, Kattankulathur, Chengalpattu, 603203, Tamilnadu, India.
  • SRM Centre for Clinical Pharmacology, Faculty of Medicine and Health Sciences, SRM Institute of Science and Technology, Kattankulathur, Chengalpattu, 603203, Tamilnadu, India. melving@srmist.edu.in.

Zitieren

APA

Masilamani, M., & George, M. (2026). Diving into the Regulatory Landscape of Digital Therapeutics. Therapeutic Innovation & Regulatory Science, 60(3), 725-735. https://doi.org/10.1007/s43441-026-00944-w

Vancouver

Masilamani M, George M. Diving into the Regulatory Landscape of Digital Therapeutics. Therapeutic Innovation & Regulatory Science. 2026;60(3):725-735. doi:10.1007/s43441-026-00944-w

BibTeX
@article{Masilamani2026,
  author = {Masilamani, Madhumitha and George, Melvin},
  title = {Diving into the Regulatory Landscape of Digital Therapeutics},
  journal = {Therapeutic Innovation & Regulatory Science},
  year = {2026},
  volume = {60},
  number = {3},
  pages = {725--735},
  doi = {10.1007/s43441-026-00944-w}
}
Kostenlos starten →